SecBot SecBot
PRESS-RELEASE ·Filed Jun 22, 2026

TCRX

TScan Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong chimerism data and planned Phase 3 initiation this month de-risk TSC-101's path to pivotal trial. Monitor for first patient enrollment announcement and any KOL event commentary on market opportunity.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8651
T+0 close · Jun 22, 2026 · via day close
Latest settled
−62.86%
T+60 · $0.3213
Vs SPY
−64.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $0.8651entry
  2. T+1 · 5mo ago +6.46%α +7.91% · $0.9210
  3. T+5 · 5mo ago +11.99%α +14.06% · $0.9688
  4. T+20 · 4mo ago +5.75%α +5.89% · $0.9148
  5. T+60 · 2mo ago −62.86%α −64.61% · $0.3213
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with all 5 patients assessed after a second infusion also achieving complete chimerism. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, supporting a bullish catalyst for this clinical-stage biotech.

Key Facts

  • 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
  • All 5 patients assessed after second infusion achieved complete chimerism
  • 93% of patients responded with decreasing recipient chimerism in higher-risk population vs Cohort A and control
  • One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT
  • Manufacturing success rate ~90% (17/19) with commercial-ready process
  • Company on track to enroll first patient in Phase 3 ALLOHA-2 study this month
  • Safety profile consistent with Cohort A; adverse events consistent with post-HCT expectations

Financial Impact

No financial data provided; clinical-stage company with no approved products or revenue

Risk Factors

  • Phase 3 trial may fail to replicate Phase 1 efficacy or safety results
  • Competition from other post-transplant relapse prevention therapies
  • Company has no approved products and will need additional financing to complete Phase 3
  • Small sample size (14 dosed patients) limits statistical reliability of current data

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3315162

Track record

15 reports on TCRX

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
  2. Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
  3. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
  4. Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
  5. Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
  6. Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
  7. Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
  8. Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 6/10 No price data
  10. Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026